Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Targeting Tumor Vascular CD99 Inhibits Tumor Growth.

Huijbers EJM, van der Werf IM, Faber LD, Sialino LD, van der Laan P, Holland HA, Cimpean AM, Thijssen VLJL, van Beijnum JR, Griffioen AW.

Front Immunol. 2019 Apr 2;10:651. doi: 10.3389/fimmu.2019.00651. eCollection 2019.

2.

Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts.

Muller J, Duray E, Lejeune M, Dubois S, Plougonven E, Léonard A, Storti P, Giuliani N, Cohen-Solal M, Hempel U, Thijssen VL, Beguin Y, Heusschen R, Caers J.

Cancers (Basel). 2019 Feb 23;11(2). pii: E261. doi: 10.3390/cancers11020261.

3.

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?

Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL.

Front Immunol. 2019 Jan 14;9:3107. doi: 10.3389/fimmu.2018.03107. eCollection 2018. Review.

4.

Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy.

Chakraborty A, Kamermans A, van Het Hof B, Castricum K, Aanhane E, van Horssen J, Thijssen VL, Scheltens P, Teunissen CE, Fontijn RD, van der Flier WM, de Vries HE.

Brain. 2018 Dec 1;141(12):3377-3388. doi: 10.1093/brain/awy274.

PMID:
30462206
5.

Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.

Thijssen VL, Paulis YW, Nowak-Sliwinska P, Deumelandt KL, Hosaka K, Soetekouw PM, Cimpean AM, Raica M, Pauwels P, van den Oord JJ, Tjan-Heijnen VC, Hendrix MJ, Heldin CH, Cao Y, Griffioen AW.

J Pathol. 2018 Dec;246(4):447-458. doi: 10.1002/path.5152. Epub 2018 Oct 30.

6.

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer.

Heeren AM, van Dijk I, Berry DRAI, Khelil M, Ferns D, Kole J, Musters RJP, Thijssen VL, Mom CH, Kenter GG, Bleeker MCG, de Gruijl TD, Jordanova ES.

Front Immunol. 2018 Jul 11;9:1598. doi: 10.3389/fimmu.2018.01598. eCollection 2018.

7.

Different angioregulatory activity of monovalent galectin-9 isoforms.

Aanhane E, Schulkens IA, Heusschen R, Castricum K, Leffler H, Griffioen AW, Thijssen VL.

Angiogenesis. 2018 Aug;21(3):545-555. doi: 10.1007/s10456-018-9607-8. Epub 2018 Mar 2.

PMID:
29500586
8.

The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.

Hamming LC, Slotman BJ, Verheul HMW, Thijssen VL.

Angiogenesis. 2017 May;20(2):217-232. doi: 10.1007/s10456-017-9546-9. Epub 2017 Mar 31. Review.

9.

Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect.

Kleibeuker EA, Fokas E, Allen PD, Kersemans V, Griffioen AW, Beech J, Im JH, Smart SC, Castricum KC, van den Berg J, Schulkens IA, Hill SA, Harris AL, Slotman BJ, Verheul HM, Muschel RJ, Thijssen VL.

Oncotarget. 2016 Nov 22;7(47):76613-76627. doi: 10.18632/oncotarget.12814.

10.

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.

Veluchamy JP, Spanholtz J, Tordoir M, Thijssen VL, Heideman DA, Verheul HM, de Gruijl TD, van der Vliet HJ.

PLoS One. 2016 Jun 17;11(6):e0157830. doi: 10.1371/journal.pone.0157830. eCollection 2016.

11.

Role of the tumor stroma in resistance to anti-angiogenic therapy.

Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW.

Drug Resist Updat. 2016 Mar;25:26-37. doi: 10.1016/j.drup.2016.02.002. Epub 2016 Feb 24. Review.

PMID:
27155374
12.

A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies.

van Beijnum JR, Thijssen VL, Läppchen T, Wong TJ, Verel I, Engbersen M, Schulkens IA, Rossin R, Grüll H, Griffioen AW, Nowak-Sliwinska P.

Int J Cancer. 2016 Aug 15;139(4):824-35. doi: 10.1002/ijc.30131. Epub 2016 May 5.

13.

Combining radiotherapy with sunitinib: lessons (to be) learned.

Kleibeuker EA, Ten Hooven MA, Verheul HM, Slotman BJ, Thijssen VL.

Angiogenesis. 2015 Oct;18(4):385-95. doi: 10.1007/s10456-015-9476-3. Epub 2015 Jul 23. Review.

14.

Galectin-1, -3 and -9 Expression and Clinical Significance in Squamous Cervical Cancer.

Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A, Jordanova ES.

PLoS One. 2015 Jun 12;10(6):e0129119. doi: 10.1371/journal.pone.0129119. eCollection 2015.

15.

Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Bajou K, Herkenne S, Thijssen VL, D'Amico S, Nguyen NQ, Bouché A, Tabruyn S, Srahna M, Carabin JY, Nivelles O, Paques C, Cornelissen I, Lion M, Noel A, Gils A, Vinckier S, Declerck PJ, Griffioen AW, Dewerchin M, Martial JA, Carmeliet P, Struman I.

Nat Med. 2015 May;21(5):537. doi: 10.1038/nm0515-537a. No abstract available.

PMID:
25951534
16.

Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer.

Punt S, Houwing-Duistermaat JJ, Schulkens IA, Thijssen VL, Osse EM, de Kroon CD, Griffioen AW, Fleuren GJ, Gorter A, Jordanova ES.

Mol Cancer. 2015 Mar 31;14:71. doi: 10.1186/s12943-015-0350-0.

17.

A common sugar-nucleotide-mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6F-GalNAc (Ac3).

van Wijk XM, Lawrence R, Thijssen VL, van den Broek SA, Troost R, van Scherpenzeel M, Naidu N, Oosterhof A, Griffioen AW, Lefeber DJ, van Delft FL, van Kuppevelt TH.

FASEB J. 2015 Jul;29(7):2993-3002. doi: 10.1096/fj.14-264226. Epub 2015 Apr 13.

18.

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.

Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL.

Cancer Med. 2015 Jul;4(7):1003-15. doi: 10.1002/cam4.441. Epub 2015 Mar 31.

19.

Galectin expression in cancer diagnosis and prognosis: A systematic review.

Thijssen VL, Heusschen R, Caers J, Griffioen AW.

Biochim Biophys Acta. 2015 Apr;1855(2):235-47. doi: 10.1016/j.bbcan.2015.03.003. Epub 2015 Mar 25. Review.

PMID:
25819524
20.

The great escape; the hallmarks of resistance to antiangiogenic therapy.

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW.

Pharmacol Rev. 2015;67(2):441-61. doi: 10.1124/pr.114.010215. Review.

PMID:
25769965
21.

Galectins in tumor angiogenesis.

Griffioen AW, Thijssen VL.

Ann Transl Med. 2014 Sep;2(9):90. doi: 10.3978/j.issn.2305-5839.2014.09.01. Review.

22.

Introduction to special issue: glycans in vascular biology.

Thijssen VL, Rabinovich GA.

Glycobiology. 2014 Dec;24(12):1235-6. doi: 10.1093/glycob/cwu093. No abstract available.

PMID:
25352647
23.

Galectin expression profiling identifies galectin-1 and Galectin-9Δ5 as prognostic factors in stage I/II non-small cell lung cancer.

Schulkens IA, Heusschen R, van den Boogaart V, van Suylen RJ, Dingemans AM, Griffioen AW, Thijssen VL.

PLoS One. 2014 Sep 26;9(9):e107988. doi: 10.1371/journal.pone.0107988. eCollection 2014.

24.

Examination of the role of galectins during in vivo angiogenesis using the chick chorioallantoic membrane assay.

Kleibeuker EA, Schulkens IA, Castricum KC, Griffioen AW, Thijssen VL.

Methods Mol Biol. 2015;1207:305-15. doi: 10.1007/978-1-4939-1396-1_20.

PMID:
25253149
25.

Examination of the role of galectins and galectin inhibitors in endothelial cell biology.

Schulkens IA, Kleibeuker EA, Castricum KC, Griffioen AW, Thijssen VL.

Methods Mol Biol. 2015;1207:285-91. doi: 10.1007/978-1-4939-1396-1_18.

PMID:
25253147
26.

Introduction to special issue: Galectins go with the flow.

Rabinovich GA, Thijssen VL.

Glycobiology. 2014 Oct;24(10):885. doi: 10.1093/glycob/cwu081. No abstract available.

PMID:
25187504
27.

Expression, regulation and function of human metallothioneins in endothelial cells.

Schulkens IA, Castricum KC, Weijers EM, Koolwijk P, Griffioen AW, Thijssen VL.

J Vasc Res. 2014;51(3):231-8. doi: 10.1159/000365550. Epub 2014 Aug 9.

PMID:
25116857
28.

PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Bajou K, Herkenne S, Thijssen VL, D'Amico S, Nguyen NQ, Bouché A, Tabruyn S, Srahna M, Carabin JY, Nivelles O, Paques C, Cornelissen I, Lion M, Noel A, Gils A, Vinckier S, Declerck PJ, Griffioen AW, Dewerchin M, Martial JA, Carmeliet P, Struman I.

Nat Med. 2014 Jul;20(7):741-7. doi: 10.1038/nm.3552. Epub 2014 Jun 15. Erratum in: Nat Med. 2014 Oct;20(10):1217. Nat Med. 2015 May;21(5):537.

PMID:
24929950
29.

Galectin-1 and -9 in angiogenesis: a sweet couple.

Thijssen VL, Griffioen AW.

Glycobiology. 2014 Oct;24(10):915-20. doi: 10.1093/glycob/cwu048. Epub 2014 May 26. Review.

PMID:
24861051
30.

Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis.

Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW, Thijssen VL.

Biochim Biophys Acta. 2014 Feb;1842(2):284-92. doi: 10.1016/j.bbadis.2013.12.003. Epub 2013 Dec 12.

31.

Involvement of galectin-1 in reproduction: past, present and future.

Barrientos G, Freitag N, Tirado-González I, Unverdorben L, Jeschke U, Thijssen VL, Blois SM.

Hum Reprod Update. 2014 Mar-Apr;20(2):175-93. doi: 10.1093/humupd/dmt040. Epub 2013 Sep 27. Review.

PMID:
24077937
32.

Interfering with UDP-GlcNAc metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesis.

van Wijk XM, Thijssen VL, Lawrence R, van den Broek SA, Dona M, Naidu N, Oosterhof A, van de Westerlo EM, Kusters LJ, Khaled Y, Jokela TA, Nowak-Sliwinska P, Kremer H, Stringer SE, Griffioen AW, van Wijk E, van Delft FL, van Kuppevelt TH.

ACS Chem Biol. 2013 Oct 18;8(10):2331-8. doi: 10.1021/cb4004332. Epub 2013 Sep 3.

33.

Vascular galectins: regulators of tumor progression and targets for cancer therapy.

Thijssen VL, Rabinovich GA, Griffioen AW.

Cytokine Growth Factor Rev. 2013 Dec;24(6):547-58. doi: 10.1016/j.cytogfr.2013.07.003. Epub 2013 Aug 12. Review.

PMID:
23942184
34.

Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia.

Freitag N, Tirado-González I, Barrientos G, Herse F, Thijssen VL, Weedon-Fekjær SM, Schulz H, Wallukat G, Klapp BF, Nevers T, Sharma S, Staff AC, Dechend R, Blois SM.

Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11451-6. doi: 10.1073/pnas.1303707110. Epub 2013 Jun 24.

35.

Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.

Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, Hooijberg E, van den Eertwegh AJ, Thijssen VL, Scheper RJ, Oosterhoff D, de Gruijl TD.

Oncoimmunology. 2013 Apr 1;2(4):e23837.

36.

Galectin-9 in tumor biology: a jack of multiple trades.

Heusschen R, Griffioen AW, Thijssen VL.

Biochim Biophys Acta. 2013 Aug;1836(1):177-85. doi: 10.1016/j.bbcan.2013.04.006. Epub 2013 May 4. Review.

PMID:
23648450
37.

Tetraspanin CD63 promotes vascular endothelial growth factor receptor 2-β1 integrin complex formation, thereby regulating activation and downstream signaling in endothelial cells in vitro and in vivo.

Tugues S, Honjo S, König C, Padhan N, Kroon J, Gualandi L, Li X, Barkefors I, Thijssen VL, Griffioen AW, Claesson-Welsh L.

J Biol Chem. 2013 Jun 28;288(26):19060-71. doi: 10.1074/jbc.M113.468199. Epub 2013 Apr 30.

38.

Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological human pregnancy.

Heusschen R, Freitag N, Tirado-González I, Barrientos G, Moschansky P, Muñoz-Fernández R, Leno-Durán E, Klapp BF, Thijssen VL, Blois SM.

Biol Reprod. 2013 Jan 25;88(1):22. doi: 10.1095/biolreprod.112.105460. Print 2013 Jan.

PMID:
23242525
39.

CXCR4(+) dendritic cells promote angiogenesis during embryo implantation in mice.

Barrientos G, Tirado-González I, Freitag N, Kobelt P, Moschansky P, Klapp BF, Thijssen VL, Blois SM.

Angiogenesis. 2013 Apr;16(2):417-27. doi: 10.1007/s10456-012-9325-6. Epub 2012 Dec 7.

PMID:
23224220
40.

Epigenetic regulation of galectin-3 expression by β1 integrins promotes cell adhesion and migration.

Margadant C, van den Bout I, van Boxtel AL, Thijssen VL, Sonnenberg A.

J Biol Chem. 2012 Dec 28;287(53):44684-93. doi: 10.1074/jbc.M112.426445. Epub 2012 Nov 1.

41.

Uterine NK cells are critical in shaping DC immunogenic functions compatible with pregnancy progression.

Tirado-González I, Barrientos G, Freitag N, Otto T, Thijssen VL, Moschansky P, von Kwiatkowski P, Klapp BF, Winterhager E, Bauersachs S, Blois SM.

PLoS One. 2012;7(10):e46755. doi: 10.1371/journal.pone.0046755. Epub 2012 Oct 8. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/9c332046-387a-4bbc-9549-2bcff73afd9a. González, Irene Tirado [corrected to Tirado-González, Irene].

42.

Combining angiogenesis inhibition and radiotherapy: a double-edged sword.

Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL.

Drug Resist Updat. 2012 Jun;15(3):173-82. doi: 10.1016/j.drup.2012.04.002. Epub 2012 May 4. Review.

PMID:
22561672
43.

Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction.

Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM.

Circulation. 2011 Oct 11;124(15):1626-35. doi: 10.1161/CIRCULATIONAHA.110.976969. Epub 2011 Sep 19.

PMID:
21931076
44.

Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer.

Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J, Kann B, Dijk WJ, Thijssen VL, Griffioen AW, Storm G, Fayad ZA, Mulder WJ.

ACS Nano. 2011 Jun 28;5(6):4422-33. doi: 10.1021/nn103336a. Epub 2011 May 25.

45.

Increased expression of distinct galectins in multiple sclerosis lesions.

Stancic M, van Horssen J, Thijssen VL, Gabius HJ, van der Valk P, Hoekstra D, Baron W.

Neuropathol Appl Neurobiol. 2011 Oct;37(6):654-71. doi: 10.1111/j.1365-2990.2011.01184.x.

PMID:
21501208
46.

Thymidine phosphorylase in cancer cells stimulates human endothelial cell migration and invasion by the secretion of angiogenic factors.

Bijnsdorp IV, Capriotti F, Kruyt FA, Losekoot N, Fukushima M, Griffioen AW, Thijssen VL, Peters GJ.

Br J Cancer. 2011 Mar 29;104(7):1185-92. doi: 10.1038/bjc.2011.74. Epub 2011 Mar 8.

47.

The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins.

Salomonsson E, Thijssen VL, Griffioen AW, Nilsson UJ, Leffler H.

J Biol Chem. 2011 Apr 22;286(16):13801-4. doi: 10.1074/jbc.C111.229096. Epub 2011 Mar 3.

48.

Tumor cells secrete galectin-1 to enhance endothelial cell activity.

Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, Hackeng TM, Kiss R, Kloog Y, Poirier F, Griffioen AW.

Cancer Res. 2010 Aug 1;70(15):6216-24. doi: 10.1158/0008-5472.CAN-09-4150. Epub 2010 Jul 20. Erratum in: Cancer Res. 2012 Feb 1;72(3):825.

49.

Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer.

Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL.

Mol Cancer. 2010 Jun 17;9:152. doi: 10.1186/1476-4598-9-152.

50.

Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor.

van Rooij E, Fielitz J, Sutherland LB, Thijssen VL, Crijns HJ, Dimaio MJ, Shelton J, De Windt LJ, Hill JA, Olson EN.

Circ Res. 2010 Jan 8;106(1):155-65. doi: 10.1161/CIRCRESAHA.109.207084. Epub 2009 Nov 5.

Supplemental Content

Loading ...
Support Center